U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07748624) titled 'A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period' on July 31.
Brief Summary: The purpose of this study is to evaluate clinical efficacy and safety of arumakimig (MAS825) compared to placebo in patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome. In addition, the study will evaluate the long-term efficacy, safety and tolerability of arumakimig in this population.
Study Start Date: Oct. 30
Study Type: INTERVENTIONAL
Condition:
VEXAS Syndrome
Intervention:
DRUG: Arumakimig
Arumakimig Injection
DRU...